Answers are grounded in this paper and cite their sources.
Prospective cohort study reports high efficacy and safety of upadacitinib in Chinese patients with inflammatory bowel disease, suggesting its therapeutic potential.
Background While upadacitinib (UPA) is an approved selective Janus kinase 1 inhibitor for moderate-to-severe Crohn’s disease (CD) and ulcerative colitis (UC), its real-world performance in Chinese patients remains underexplored. This prospective study aims to report real-world data on efficacy and safety of UPA in Chinese patients with inflammatory bowel disease (IBD). Methods This is a single-center, prospective cohort study from the IBD center of Sir Run Run Shaw Hospital. Moderate-to-severe patients with CD and UC who initiated UPA treatment between September 1, 2023, and July 31, 2025 were enrolled. Data on patient characteristics, treatment paradigm, efficacy, and adverse events (AEs) were collected. Results This study enrolled 253 patients (203 CD; 50 UC) with median disease durations of 7.9 and 4.4 years, respectively. All patients were biologic-experienced, with 56.2% of CD and 60.0% of UC having failed ≥2 advanced therapy lines. For CD, at week 12/52, clinical remission rates were 70.3% (123/175) and 68.2% (73/107). Endoscopic remission rates were 34.0% (34/100) and 34.8% (23/66) (Figure 1A). Multivariate analysis identified lower body mess index, higher baseline Crohn’s disease activity index, and third-line advanced therapies as independent factors associated with reduced likelihood of clinical remission at week 12. For UC, clinical remission rates increased from 55.3% (21/38) at week 12 to 90.0% (18/20) at week 52. Endoscopic remission was observed in 66.7% (20/30) and 81.3% (13/16), respectively (Figure 1B). Perianal disease resolution was observed in 47.1% (72/153) in CD. Extraintestinal manifestation (EIM) resolution rates were 77.8% (21/27) in CD and 66.7% (2/3) in UC. Treatment discontinuation rates were 22.7% for CD and 36.0% for UC, primarily due to inadequate response (CD: 16.3%; UC: 12.0%), followed by AEs (CD: 5.4%; UC: 14.0%). Regarding safety, AEs possibly related to UPA occurred in 35.0% (71/203) of CD and 30.0% (15/50) of UC, while severe AEs occurred in17.2% and 18.0%, respectively. The most common AEs were cutaneous manifestations, respiratory reactions, and anemia in CD; and cutaneous manifestations, herpes zoster infection, and opportunistic infections in UC. Conclusion This prospective real-world study validates UPA as a highly effective and well-tolerated treatment option for a predominantly biologic-refractory Chinese IBD population. UPA induced high rates of clinical and endoscopic remission and demonstrated meaningful efficacy in resolving perianal disease and EIMs, thereby addressing core unmet needs. Together with a manageable safety profile, these robust data affirm a favorable benefit-risk profile for UPA in this challenging-to-treat cohort. Reference: Not available. Conflict of interest: Dr. Yao, Lingya: No conflict of interest Xu, Yining: No conflict of interest Xia, Wenhao: No conflict of interest Cao, Qian: No conflict of interest
No takes yet. Share an insight, caveat, or question.
Yao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: